Marketed Drgus:
4 EXECUTIVE SUMMARY
5 PRODUCT OVERVIEW
5 Key marketed drugs for atopic dermatitis
7 PRODUCT PROFILES
7 Elidel : Atopic dermatitis
15 Elocon : Atopic dermatitis
23 Medrol : Atopic dermatitis
28 Protopic : Atopic dermatitis
43 Toctino : Atopic dermatitis
5 Figure 1: Datamonitor Healthcare’s drug assessment summary for atopic dermatitis
10 Figure 2: Elidel for atopic dermatitis – SWOT analysis
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of Elidel in atopic dermatitis
11 Figure 4: Datamonitor Healthcare’s drug assessment summary of Elidel in atopic dermatitis
17 Figure 5: Elocon for atopic dermatitis – SWOT analysis
18 Figure 6: Datamonitor Healthcare’s drug assessment summary of Elocon in atopic dermatitis
19 Figure 7: Datamonitor Healthcare’s drug assessment summary of Elocon in atopic dermatitis
37 Figure 8: Protopic for atopic dermatitis – SWOT analysis
38 Figure 9: Datamonitor Healthcare’s drug assessment summary of Protopic in atopic dermatitis
39 Figure 10: Datamonitor Healthcare’s drug assessment summary of Protopic in atopic
dermatitis
5 Table 1: Key marketed drugs for atopic dermatitis
7 Table 2: Elidel drug profile
9 Table 3: Elidel pivotal trial data in atopic dermatitis
15 Table 4: Elocon drug profile
24 Table 5: Medrol/Depo-Medrol drug profile
28 Table 6: Protopic drug profile
31 Table 7: Protopic US pivotal trial data in atopic dermatitis
34 Table 8: Protopic EU pivotal trial data in atopic dermatitis
36 Table 9: Protopic pivotal trial data supporting use as a maintenance treatment in atopic
dermatitis
37 Table 10: Protopic late-phase trial data in atopic dermatitis
43 Table 11: Toctino drug profile
45 Table 12: Toctino US pivotal trial data in severe chronic hand dermatitis
Forecast:
5 EXECUTIVE SUMMARY
6 MARKET OVERVIEW AND TRENDS
6 Current and future market dynamics overview
12 Bibliography
14 MARKET DEFINITION AND METHODOLOGY
14 Market definition for atopic dermatitis
16 Forecast methodology and assumptions
25 Bibliography
27 CRISABOROLE
27 Forecast assumptions
28 Crisaborole forecast, 2015–24
29 Bibliography
30 DUPILUMAB
30 Forecast assumptions
31 Dupilumab forecast, 2015–24
33 Bibliography
35 ELIDEL (PIMECROLIMUS)
35 Forecast assumptions
37 Elidel forecast, 2015–24
38 Bibliography
39 ELOCON (MOMETASONE FUROATE)
39 Forecast assumptions
42 Elocon forecast, 2015–24
43 Bibliography
45 PROTOPIC (TACROLIMUS)
45 Forecast assumptions
47 Protopic forecast, 2015–24
48 Bibliography
50 PRIMARY RESEARCH METHODOLOGY
50 Physician research
51 Key opinion leader research

6 Figure 1: Atopic dermatitis sales across the US, Japan, and five major EU markets, by country, 2015–24
8 Figure 2: Dupilumab sales for atopic dermatitis across the US, Japan, and five major EU
markets, by country, 2015–24
10 Figure 3: Crisaborole sales for atopic dermatitis in the US, 2015–24
16 Figure 4: Patient-based forecast methodology for atopic dermatitis
21 Figure 5: Price sources and calculations, by country
28 Figure 6: Crisaborole sales for atopic dermatitis in the US, 2015–24
31 Figure 7: Dupilumab sales for atopic dermatitis across the US, Japan, and five major EU
markets, by country, 2015–24
37 Figure 8: Elidel sales for atopic dermatitis across the US, Germany, Italy, Spain, and the UK, by
country, 2015–24
42 Figure 9: Elocon sales for atopic dermatitis across the US, Japan, Germany, Italy, Spain, and
the UK, by country, 2015–24
47 Figure 10: Protopic sales for atopic dermatitis across the US, Japan, and five major EU
markets, by country, 2015–24
14 Table 1: Summary of drug classes and molecules included in Datamonitor Healthcare’s
patient-based atopic dermatitis forecast
17 Table 2: Atopic dermatitis severity definitions
23 Table 3: Exchange rates used for calculating prices
24 Table 4: Patent expiry dates for key marketed brands in atopic dermatitis across the US, Japan,
and five major EU markets, by region
24 Table 5: Forecast launch dates of generic versions of key marketed brands in atopic dermatitis
across the US, Japan, and five major EU markets, by region, 2015–24
24 Table 6: Forecast launch dates of key late-phase pipeline products in atopic dermatitis across
the US, Japan, and five major EU markets, by country, 2015–24
28 Table 7: Crisaborole sales for atopic dermatitis in the US ($m), 2015–24
32 Table 8: Dupilumab sales for atopic dermatitis across the US, Japan, and five major EU
markets, by country ($m), 2015–24
36 Table 9: Datamonitor Healthcare’s price assumptions for Elidel
37 Table 10: Elidel sales for atopic dermatitis across the US, Germany, Italy, Spain, and the UK, by
country ($m), 2015–24
41 Table 11: Datamonitor Healthcare’s price assumptions for Elocon in atopic dermatitis, by
country
42 Table 12: Elocon sales for atopic dermatitis across the US, Japan, Germany, Italy, Spain, and
the UK, by country ($m), 2015–24
46 Table 13: Datamonitor Healthcare’s price assumptions for Protopic
47 Table 14: Protopic sales for atopic dermatitis across the US, Japan, and five major EU markets,
by country ($m), 2015–24
50 Table 15: Dermatologists surveyed for the atopic dermatitis primary research study, 2015

Pipeline:
CONTENTS
LIST OF FIGURES
LIST OF TABLES
4 EXECUTIVE SUMMARY
5 CLINICAL PIPELINE OVERVIEW
5 Pipeline summary
6 LATE STAGE DRUGS
6 crisaborole : Atopic dermatitis
15 dupilumab : Atopic dermatitis
10 Figure 1: Crisaborole for atopic dermatitis – SWOT analysis
11 Figure 2: Datamonitor Healthcare’s drug assessment summary of crisaborole in atopic
dermatitis
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of crisaborole in atopic
dermatitis
20 Figure 4: Dupilumab for atopic dermatitis – SWOT analysis
21 Figure 5: Datamonitor Healthcare’s drug assessment summary of dupilumab in atopic
dermatitis
21 Figure 6: Datamonitor Healthcare’s drug assessment summary of dupilumab in atopic
dermatitis
5 Table 1: Pipeline products in development for atopic dermatitis
6 Table 2: Crisaborole drug profile
8 Table 3: Crisaborole Phase III trials in atopic dermatitis
15 Table 4: Dupilumab drug profile
18 Table 5: Dupilumab Phase III trials in atopic dermatitis

Treatment:
CONTENTS
5 EXECUTIVE SUMMARY
6 PRIMARY RESEARCH METHODOLOGY
6 Physician research
10 DISEASE DEFINITION AND DIAGNOSIS
10 Disease definition
10 Diagnosis
12 Risk factors
12 Co-morbidities
13 Affected areas
13 Bibliography
16 PATIENT SEGMENTATION
16 Available disease severity measurement scales are rarely used in routine clinical practice
17 Bibliography
19 COUNTRY TREATMENT TREES
19 Introduction to treatment trees
20 CURRENT TREATMENT OPTIONS
20 Treatment guidelines
20 Overview of the available therapies
22 Bibliography
23 PRESCRIBING TRENDS
23 The majority of treated atopic dermatitis patients receive pharmacological therapy in
combination with non-pharmacological therapy
28 Bibliography
29 PERSISTENCE AND COMPLIANCE
29 Persistence increases with disease severity due to increased patient motivation
30 Oral administration ensures higher compliance rates compared to topical application
31 Bibliography
32 UNMET NEEDS IN ATOPIC DERMATITIS
35 Development of a novel systemic therapy for severe refractory atopic dermatitis remains
among the most prominent unmet needs
38 Bibliography
40 PRESCRIBING INFLUENCES
44 PIPELINE DRUGS AND FUTURE TREATMENT
44 Surveyed dermatologists reveal a positive outlook for dupilumab
45 Bibliography
10 Figure 1: Criteria considered in the diagnosis of atopic dermatitis
17 Figure 2: Atopic dermatitis patient segmentations across the US, Japan, and five major EU
markets, by disease severity
23 Figure 3: Use of pharmacological, non-pharmacological, and pharmacological + nonpharmacological
therapy for the treatment of atopic dermatitis, by severity
29 Figure 4: Annual prescriptions filled by atopic dermatitis patients, by disease severity and
country (%)
30 Figure 5: Compliance rates for atopic dermatitis treatment across the US, Japan, and five
major EU markets, by formulation type and country (%)
35 Figure 6: Top three treatment challenges in atopic dermatitis
7 Table 1: Dermatologists surveyed for the atopic dermatitis primary research study, 2015
16 Table 2: Atopic dermatitis severity definitions
20 Table 3: Summary of key classes and products included in Datamonitor Healthcare’s 2015
atopic dermatitis primary market survey
25 Table 4: Atopic dermatitis patients who receive non-pharmacological, pharmacological, and
pharmacological + non-pharmacological therapy, by country
33 Table 5: Relative importance of treatment challenges in atopic dermatitis
41 Table 6: Relative importance of factors that influence dermatologists’ prescribing behavior in
atopic dermatitis, by country
44 Table 7: Expected share of diagnosed atopic dermatitis patients for currently approved and
pipeline agents five years after launch, by country and agent (%)